Fresenius SE & Co. KGaA Increases 2024 Financial Outlook

Fresenius SE & Co. KGaA announced an updated financial outlook for the fiscal year 2024, attributing the adjustment to a strong performance in the first quarter and better-than-expected operational results anticipated for the remaining year. The company now forecasts organic group revenue growth of 4 to 7%, a revision from the previously estimated 3 to 6%.

The expected growth in Group EBIT at constant currency is also adjusted, with a new range of 6 to 10%, up from 4 to 8% as earlier projected. This positive revision is largely driven by improved business prospects within its Fresenius Kabi division, which now expects organic revenue growth in the mid to high single-digit percentage range for 2024, compared to previous expectations of just the mid single-digit range.

Additionally, updated projections for Fresenius Kabi include an EBIT margin between 15 and 16%, an increase from the earlier forecast of around 15%. The revised outlook excludes operations from Fresenius Vamed, focusing solely on the core operating companies—Fresenius Kabi and Fresenius Helios—following the planned divestment of Fresenius Vamed’s rehabilitation business.